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Background: The quality and safety of advanced therapy products must be maintained throughout their
production and quality control cycle to ensure their final use in patients. We validated the cell count method
according to the International Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use and European Pharmacopoeia, considering the tests’ accuracy, precision,
repeatability, linearity and range.
Methods: As the cell count is a potency test, we checked accuracy, precision, and linearity, according to ICH Q2.
Briefly our experimental approach was first to evaluate the accuracy of Fast Read 102W compared to the Bürker
chamber. Once the accuracy of the alternative method was demonstrated, we checked the precision and linearity
test only using Fast Read 102W. The data were statistically analyzed by average, standard deviation and coefficient
of variation percentages inter and intra operator.
Results: All the tests performed met the established acceptance criteria of a coefficient of variation of less than ten
percent. For the cell count, the precision reached by each operator had a coefficient of variation of less than ten
percent (total cells) and under five percent (viable cells). The best range of dilution, to obtain a slope line value very
similar to 1, was between 1:8 and 1:128.
Conclusions: Our data demonstrated that the Fast Read 102W count method is accurate, precise and ensures the
linearity of the results obtained in a range of cell dilution. Under our standard method procedures, this assay may
thus be considered a good quality control method for the cell count as a batch release quality control test.
Moreover, the Fast Read 102W chamber is a plastic, disposable device that allows a number of samples to be
counted in the same chamber. Last but not least, it overcomes the problem of chamber washing after use and so
allows a cell count in a clean environment such as that in a Cell Factory. In a good manufacturing practice setting
the disposable cell counting devices will allow a single use of the count chamber they can then be thrown away,
thus avoiding the waste disposal of vital dye (e.g. Trypan Blue) or lysing solution (e.g. Tuerk solution).
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The use of human cell based medical products (hCBMPs)
in a patient-specific manner for cell therapy purposes raises
specific issues pertaining to quality control testing designs
for each product under examination [1]. European Com-
munity (EC) Directive 2001/83/EC relating to medicinal
products for human use defines a hCBMP as a medicinal
product which has properties to treat or prevent disease in
human beings. Regulations and guidelines for CBMP pro-
duction follow those of conventional medicinal products
[2-4]. The European Parliament Regulation N. 1394/2007
on advanced therapy medicinal products, amending the
2001/83/EC Directive, completed the regulatory setting on
advanced therapies to be used in Member States [5]. The
manufacturing process of CBMPs has to comply with the
principles and guidelines of good manufacturing practice
(GMP) for medicinal products for human use published by
the European Commission [6,7]. GMP ensures that pro-
ducts are consistently produced and controlled to the qual-
ity standards required for their intended use, from the
collection and manipulation of raw materials to the proces-
sing of intermediate products, the quality controls, storage,
labelling and packaging, and release. In general, when a
CBMP enters the clinical development phase, the same
principles as those for other medicinal products apply [8].
There should be a careful design and validation of the en-
tire manufacturing process of CBMPs, including cell har-
vesting, cell manipulation processes, the maximum number
of cell passages, and combinations with other components
of the product, filling, packaging, etc. In order to ensure
product safety and efficacy, each step of the manufacturing
process of active substances and supportive components
should all be demonstrated, as should be the control of the
final product. The quality and safety of the cell preparations
should be ensured by implementing a quality system that
guarantees the certification and the traceability of every
batch of material and supply utilized for the procedures
and the correct utilization and cleaning of instruments and
locations necessary for stem cell manipulation. Further-
more, the organization structure, qualification and training
status of the personnel, and the appropriate equipment,
should also comply with current GMP standards. An im-
portant aspect of advanced therapies is the necessity to
process CBMPs in an aseptic environment, to avoid ter-
minal sterilization which would lead to damage to, and the
ineffectiveness of, the cell product. Each manufacturing op-
eration requires an appropriate environmental cleanliness
level in the operational state to minimize the risks of
particulate or microbial contamination of the product or
materials being handled. The application of the GMPs for
aseptic production, besides checking all the aspects related
to the process, is aimed at minimizing possible contamin-
ation factors (personnel, environment, equipment, manu-
facturing and storage conditions) to ensure the safety of thefinal product. The quality and safety of advanced therapy
products must be maintained throughout their production
and quality control (QC) cycle, thus ensuring their final use
in the patient. An extensive characterization of the cell
therapy product (CTP) should be established in terms of
identity, purity, potency and suitability for their intended
use. In this context, the cell count, that will indicate the
CTP dose, is a potency test. On these bases we validated
the cell count method according to the International Con-
ference on Harmonization (ICH) Q2 Guidelines [9] and
European Pharmacopoeia (EP) [10], taking into account the
tests’ accuracy, precision, repeatability, linearity and range.
According to the ICH Q2 [9]: “accuracy expresses the
closeness of agreement between the value which is accepted
as either a conventional true value or as an accepted refer-
ence value and the value found; precision of an analytical
procedure expresses the closeness of agreement (degree of
scatter) between a series of measurements obtained from
the multiple sampling of the same homogeneous sample
under the prescribed conditions; repeatability (also termed
intra-assay precision) expresses the precision under the
same operating conditions over a short interval of time;
linearity of an analytical procedure is its ability (within a
given range) to obtain test results which are directly pro-
portional to the concentration of an analyte in the same
sample”. There are various manual or automatic, cell count
methods. Among the manual cell count methods, the Bür-
ker chamber is seen as the reference method and is the only
one described in EP [10]. Alternative manual cell counting
chambers include the following: Malazzes, Thoma, Lemaur,
Nageotte, Neubauer, Neubauer impaired, Agasse Lafont,
and Fuch-Rosenthal. These devices basically differ in the
type of ruling that they also have cover glasses of different
sizes for the counting chamber. All these double net rulings
are made of glass and are not disposable. There are also dis-
posable cell count devices as Kovas slides and Fast Read
102 W slides. In a GMP setting the latter devices will allow
the count chamber to be used only once and then be
trashed so that the disposal of waste of vital dye (e.g. Try-
pan Blue) or lysing solution (e.g. Tuerk solution) can be
avoided. Moreover, although some automatic counters are
marketed, for GMP settings, their associated software
should comply with 21 CFR Part 11 [11-14]. On these
bases, our primary aim was to validate a disposable cell
count method in GMP conditions, to be included in the
Validation Master Plan (VMP) to be submitted to the Regu-
lators, to obtain accreditation of our Cell Factory to pro-
duce CTPs. We decided to use a manual cell count and
validate, according to GMP rules, a disposable device, Fast
Read 102 W, already used in P3 laboratory by our group.
We therefore sought to evaluate whether Fast Read
102 W could substitute the Bürker chamber in terms of
accurancy. Once this hypothesis was proved, we tested
repeatability, linearity and range only using Fast Read
Gunetti et al. Journal of Translational Medicine 2012, 10:112 Page 3 of 12
http://www.translational-medicine.com/content/10/1/112102 W. Two cell subpopulations were chosen for the val-
idation procedure: mononuclear cells (MNCs), as a
prototype of lymphocytes, and mesenchymal stem cells
(MSCs), both cell therapy products (CTP) that we will
produce for immunotherapy and regenerative medicine.
In these settings, we validated viability by Trypan Blue
dye. We isolated MNCs and MSCs from whole periph-
eral blood (wPB) and whole bone marrow (wBM) re-
spectively. We also validated the wPB and wBM cell
counts, using Tuerk dye as a red cell lysing solution, to
establish the best range of a sample dilution. Finally, the
outcome of this experiment served to test whether, hav-
ing found the dilution range, it might also be suitable for
the MNC and MSC counts.
Methods
The cell count validation protocol was performed as
shown in the flow chart (Figure 1). We used two different
cell products, MNCs and MSCs. The validation procedure
was performed by two operators (Op): Op1 and Op2.
MNC isolation
PB, obtained from healthy donors after informed con-
sent, was layered on a Hystopaque (Sigma Aldrich,
Milan, Italy) gradient (1.077 g/ml density). The cells
were centrifuged at 400 g for 30 minutes. The cells in
the interphase were collected, washed twice with phos-
phate buffered saline (PBS) 1X (200 g for 10 minutes)
and resuspended in CellGrowW SCGM Medium (Cell
Genix, Freiburg Germany) containing 5% of Human Sera
Type AB (Lonza, Verviers, Belgium).
BM MSC isolation and expansion
Whole Bone Marrow (wBM) MSCs were isolated from
human BM obtained by aspiration from the posterior iliac
crest of healthy donors after written informed consent. The
MSC frequency in BM was about 1/104 cells [15]. Briefly,
wBM was seeded at a density of 100,000/cm2 in Mesen-
CultW Proliferation Kit (MCPK) (Stemcell Technologies,
Vancouver, BC, Canada) in 75 or 150 cm2 T-flasks and
maintained at 37°C with a 5% CO2 atmosphere. After
5 days, the non-adherent cells were removed and re-feeded
every three to four days. At confluence, they were detached,
and re-plated at different densities for one to four passages
[16]. To perform the cell count procedure, at the second-
fourth passages of culture (P2-P4), the MSCs were
detached and resuspended in MCPK.
Bürker cell count
The Bürker chamber (Figure 2A) has 9 large squares
(1 mm2 each), divided by double lines (0.05 mm apart)
into 16 group squares. The double lines form small
0.0025 mm2 squares. The Chamber depth is 0.1 mm.
The cells were counted as reported in Figure 2A. Briefly,both operators take 10 μl of cell suspension with a
micropipette and put them in the cell count chamber
and then count the cells in each of the 4 large squares
(identified by the triple line and shaded in the figure). At
the end of the procedure the operators calculate the
average of the 4 readings (from 4 large squares) and cal-
culate the cell concentration as follows:
Cell
ml
 
¼
P
cell counted in4 large squares
4
 
 dilution factorð Þ  1 104
Fast Read 102W cell count
The Bürker chamber cell count was compared to the
Fast Read 102W count. The Fast Read 102W is a plastic
slide, with 10 chambers, that allows single-use, quickly
and effectively, and the simultaneous reading of 10 cell
counts. The operators transferred 10 μl of cell suspen-
sion to be analysed into each chamber and by capillary
action the cell suspension filled the corresponding
chamber, allowing a quick read with a microscope. De-
pending on the focus adjustment of the microscope, the
cells can be counted and seen as reflective spheres. The
cells were counted as reported in Figure 2B. Briefly, both
operators counted the cells in 5 large squares, and calcu-
lated the average of the counts to reduce the margin of
error. In each large square, they counted all the cells
contained in the 16 small squares, including the internal
dividing lines. Thus, for each chamber (square size 1 x
1 mm, square depth 0.1 mm and square volume 0.1 μl),
the cell count per ml was performed using the following
formula:
Cells
ml
 
¼
P
cells counted in5 squares
5
 
 dilution factorð Þ  1 104
Accuracy
Accuracy was checked, as above reported, according to
ICH Q2 [9]. The test was performed on MNCs, by Ops1
and 2, three times under the same operating conditions.
The concentration of the cell suspension was previously
quantified using the Bürker chamber. To evaluate accur-
acy, the results obtained with the Bürker chamber were
compared to those obtained by using the Fast Read
102W chamber. As for accuracy test, the Ops had to
count repeated on the same day with the same sample,
to avoid the possibility that the time had affected the cell
viability, in this first step of experiments, the accuracy
test was performed on total cells without considering
cell viability.
Figure 1 Cell count validation protocol. According to ICH Q2, the test was performed three times under the same operating conditions by
Op1 and Op2. The concentration of the cell suspension was previously quantified using the Bürker chamber. Both operators then evaluated the
accuracy of the method comparing the Bürker chamber with the Fast Read 102W chamber, performing a total (non-viable) cell count. In order to
evaluate the precision and the repeatability of the method, intra and inter operator CV% was calculated using a viable cell count by Trypan Blue
vital dye. The acceptance criteria were: inter and intra operator CV%< 10 % (total cell count); intra and inter operator CV%< 5 % (viable cell
count). For linearity, we tested serial dilutions, in the following range: undiluted, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128. Op1 and Op2 performed a total
cell count three times for each dilution. On the basis of the results, the regression line was calculated and the optimal range of dilutions was
determined.
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the overlapping of cell count data by the two above
described methods, we decided to use the disposable Fast
Read 102W chamber, instead of the Bürker chamber, for all
subsequent tests.Precision and repeatability
On the bases of accuracy results, the precision and repeat-
ability were assayed, according to ICH Q2 [9], using the
Fast Read 102W chamber. The test was performed on
MNCs and MSCs, by Ops1 and 2, three times under the
Figure 2 Bürker chamber and Fast Read 102W cell count method. The Bürker chamber has 9 large squares (1 mm2 each), divided by double
lines (0.05 mm apart) into 16 group squares. The double lines form small 0.0025 mm2 squares. The Chamber depth is 0.1 mm. The cells were counted
in each of the 4 large squares (identified by the triple line and shaded in the figure). At the end of the procedure the operators calculate the average
of the 4 readings (from 4 large squares) and calculate the cell concentration as follows: Cellml
  ¼
P
cells counted in 4 squares
4
 
 dilution factor  104. Fast
Read 102W chamber, a plastic device with a slide divided into 10 chambers. Each chamber contains a grid with 10 squares, subdivided into 16 small
squares. When the chamber was filled, the cells distributed in the 5 squares (black lines) were counted, taking into consideration, for each chamber, a
size of 1 x 1 mm, a depth of 0.1 mm and a volume of 0.1 μl per square, the cell concentration (cells/ml) was determined by the formula:
Cell
ml
  ¼
P
cells counted in 5 squares
5
 
 dilution factor  104.
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evaluated cell viability, using Trypan Blue vital dye.Viability cell counting by Trypan Blue dye
For viable cell counting the cell suspension was diluted 1:2
by Trypan Blue dye. Briefly, the Ops take, by micropipette,
10 μl of cell suspension and diluted it, by pipetting, with an
equal volume of Trypan Blue dye. They then transferred
10 μl of this diluted cell suspension, to be analysed, into
each chamber of the Fast Read 102W slides.Linearity and range on wPB and wBM count
In order to test these two analytical methods, as we
had isolated MNCs and MSCs cells from wPB and
wBM respectively, first we decided to check linearity
and range, using Fast Read 102W, on these viscous
tissues highly enriched in red blood cells (RBC). For
this purpose, according to ICH Q2 [9], Ops used
serial diluitions in the following ranges: undiluted,
1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128. We then diluted
10 μl of wPB and wBM with different volumes of
Tuerk lysing (Fluka), an acetic acid and gentian
Figure 3 Accuracy. Accuracy data demonstrated that the cell count obtained by the disposable Fast Read 102W cell count device is comparable
to the Bürker cell count. Each Operator calculated the average and SD of its three counts for both counting devices to obtain the intra operator
CV%. Op1 and Op2 then calculated intra operator CV% between Bürker vs Fast Read102W (a: Op1 raw data; b: Op2 raw data). Finally, inter
operator CV% (Bürker vs Fast Read 102W) was reported (c). CV= coefficient of variation, Op1 = operator 1, Op2= operator 2.
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Figure 4 Precision and Repeatability on MNCs. On the basis of accuracy data, the following experiments were made to test precision,
repeatability, linearity and range only by using Fast Read 102W. The assay was performed only using the Fast Read 102W chamber on MNCs.
Operators 1 and 2 tested their cell counts three times. Cell viability was evaluated using Trypan Blue vital dye with a 1:2 dilution. To obtain the
intra operator CV%, each operator calculated the average and SD of their three counts (a): Op1 raw data; (b): Op2 raw data. The inter operator CV
% viability was then calculated (c). CV = coefficient of variation, MNC=mononuclear cells, Op1 = operator 1, Op2 = operator 2.
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nuclei of white blood cells (WBC) blue. To avoid
any potential Tuerk lysing solution or Trypan Blue
vital dye interference, the test only considers total
cell count and not cell viability. The Ops performed
the cell count three times for each dilution. On the
basis of the results, the regression line was calcu-
lated and the optimal range of dilutions was
determined.
Linearity and range on MNCs and MSCs
According to ICH Q2 [9], as above described, we also
tested linearity and range on MNCs and MSCs using
serial dilutions, in the following ranges: undiluted, 1:2,
1:4, 1:8, 1:16, 1:32, 1:64, 1:128. Ops 1 and 2 performed
the cell count three times for each dilution. The test was
performed without considering cell viability to be com-
pared to previous described data on wPB and wBM. On
the basis of the results, the regression line was calculated
and the optimal range of dilutions was determined.
Statistical analysis
The statistical analysis was performed by calculating
average, standard deviation (SD) and inter and intra op-
erator coefficients of variation (CV%).The accuracy of the method was determined by calcu-
lating inter and intra operator CV% (Bürker vs Fast
Read 102W chamber); similarly, the precision and the re-
peatability of the method were established by evaluating
the inter and intra operator CV%.
The acceptance criteria for accuracy was, as shown in
the flow chart in Figure 1, CV%< 10 % (total cell count).
For precision and repeatability, the acceptance criteria
were, as shown in the flow chart in Figure 1, CV%< 5%
(viable cell count). The regression line was calculated for
linearity and the range test.
Statement of ethical approval
Bone Marrow (BM) and peripheral blood (PB) were
obtained from healthy donors after written informed
consent in accordance with the approval of the Ethics
Committees, of the Regina Margherita, S.Anna and
Mauriziano hospitals, and in compliance with the Hel-
sinki Declaration.
Results and discussion
Our primary aims were to validate, in a GMP conditions,
a disposable cell count method to be included in a Valid-
ation Master Plan (VMP) to be submitted to the Regula-
tors, in order to obtain the accreditation of our Cell
Figure 5 Precision and Repeatability on MSCs. As previously reported, also for MSCs, the assay was performed only using the Fast Read 102W
chamber on MSCs. Operators 1 and 2 tested their cell counts three times. Cell viability was evaluated using Trypan Blue vital dye with a 1:2
dilution. To obtain the intra operator CV%, each operator calculated the average and SD of their three counts (a: Op1 raw data; b: Op2 raw data).
The inter operator CV% viability was then calculated (c). CV= coefficient of variation, MSC=mesenchymal stem cells, Op1 = operator 1,
Op2 = operator 2.
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is a potency test, according to EP, which define the cell
dose during ex-vivo expansion and batch release. In a
GMP setting the cell counting using disposable devices
is a very important starting point as it will allow the sin-
gle use of the count chamber and thus avoid disposal of
vital dye (e.g. Trypan Blue) or lysing solution (e.g. Tuerk
solution). As we had experience on cell counting by Fast
Read 102 W slides (despite there being other disposable
cell count chambers availble), we first tested whether
Fast Read 102 W devices might substitute Bürker cham-
ber in terms of accuracy. Once this hypothesis was
proved, we tested repeatability, linearity and range only
using Fast Read 102 W. Two cell subpopulations were
chosen for the validation procedure: MNCs, as a subset
of lymphocytes, and MSCs: both CTPs that we will pro-
duce for immunotherapy and regenerative medicine.
To minimize the error due to the diverse pipetting
procedures, the operators standardized this critical issue.
This practice was especially necessary because, in order
to standardize the procedure, we decided to use forward
pipetting for wPB, wBM and for less viscous cell
suspensions.
For every test (accuracy, precision, repeatability, linearity
and range) the Ops, according to ICH Q2, performed
three cell counts, under the same operating conditions.Three repetitions for each count was sufficient for a
statistical analysis and, moreover, the CV% and SD we
obtained corroborate, in our opinion, our experimental
approach.
On the basis of the accuracy test once we had vali-
dated the overlapping of cell count data by both above
described methods, we decided to use the disposable
Fast Read 102W chamber, instead of the Bürker chamber,
for all subsequent tests.
Accuracy
As accuracy expresses the closeness of agreement be-
tween the value, which is accepted as either a conven-
tional true value or as an accepted reference value and
the value found, we decided that the use of MNCs was
sufficient to validate this point of method.
Ops 1 and 2 performed their cell count three times.
First with the Bürker chamber, the standard cell count
method described in EP, in order to detect the exact cell
suspension concentration, and then with the Fast Read
102W chamber. As already explained above, since this
first phase was lengthy, we decided to avoid evaluating
cell viability that would have distorted the results.
Each operator calculated the average and SD of its three
counts for both count devices to obtain the intra operator
CV%. All the data obtained are summarized in Figure 3.
Figure 6 Linearity and range on wPB and wBM. Linearity and range was evaluated by Fast Read 102 W device, as above described. The assay
was performed on wPB (A) and wBM (B). The Operators tested different dilutions of cell suspension with Tuerk solution (undiluted, 1:2, 1:4, 1:8,
1:16, 1:32, 1:64, 1:128) in order to verify the best range of dilution to use. To avoid any potential interference of the Tuerk lysing solution and the
Trypan Blue vital dye, in this case, the test only considers the total cell count and not cell viability. The regression line was calculated using the
average of values obtained from Op1 and Op2’s counts at each dilution. The best range of dilution, in order to obtain a slope line value very
similar to 1, is between 1:8 and 1:128. a1) wPB dilution range: 1:4, 1:8, 1:16, 1:32, 1:64, 1:128; a2) wPB dilution range: 1:8, 1:16, 1:32, 1:64, 1:128; b1)
wBM dilution range: 1:4, 1:8, 1:16, 1:32, 1:64, 1:128; b2) wBM dilution range: 1:8, 1:16, 1:32, 1:64, 1:128. Op1= operator 1, Op2 = operator 2.
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%=2; Op2 (Bürker): CV%=8.2; Op1 (Fast Read102W): 1.1;
Op2 (Fast Read102W): 7.5]. Op2’s CV% in the accuracy test-
ing was very high compared to Op1’s, but fulfills the estab-
lished acceptance criteria (< 10%). This CV% appears
much lower when testing precision and repeatability prob-
ably due to the improvement of the confidence with the
method. Ops 1 and 2 then had to calculate intra operator
CV% (Bürker vs Fast Read102W): similarly, the intra oper-
ator CV% was <10 % [intra Op1 CV% (Bürker vs Fast
Read102W) = 0.3; intra Op2 CV% (Bürker vs Fast
Read102W) = 8.3]. Finally, inter operator CV% (Bürker vs
Fast Read 102W) was calculated and was under 10% [CV%
(Op1-Op2 Bürker) =6.1; CV% (Op1-Op2 Fast Read
102W) = 2.5; CV% (Op1-Op2 Bürker vs Fast Read
102W) = 4]. As the accuracy and repeatability criteria were
satisfied, Fast Read 102W was considered comparable to
Bürker chamber and so the following tests were performed
only with the disposable Fast Read 102W chamber.
Precision and repeatability
As previously and amply explained above, the test was per-
formed on MNCs and on MSCs using the Fast Read 102W
chamber. Op1 and Op2 performed the cell count three
times. The cell viability was evaluated using Trypan Bluevital dye, with a 1:2 dilution, as above described. To obtain
the intra operator CV%, Op1 and Op2 calculated the aver-
age and SD of their three counts for each cell type (MNCs
and MSCs). All the data are summarized in Figures 4
(MNCs) and 5 (MSCs). For both MNCs and MSCs, the via-
bility intra operator CV% was <5% [Op1 (MNCs): CV
%=0.5; Op2 (MNCs): CV%=1.8 ; Op1 (MSCs): CV
%=4.4; Op2 (MSCs): CV%=2.7], thus demonstrating the
repeatability of operators. Ops 1 and 2 then calculated the
viability of inter operator CV% [CV% (Op1-Op2 MNCs)=
2.8; CV% (Op1-Op2 MSCs)=4.2]. These data demon-
strated that the method is valid as it is both repeatable and
precise.
Linearity and range on wPB and wBM
In order to test these two analytical methods, as we iso-
lated MNCs and MSCs cells from wPB and wBM re-
spectively, first we decided to set up linearity and range,
according to ICH Q2, using serial dilution ranges (un-
diluted ranges: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128) of
these viscous tissues that are highly enriched in red
blood cells (RBC), with the Tuerk lysing solution above
described. To avoid any potential interference of the
Tuerk lysing solution and the Trypan Blue vital dye, in
this case, the test only considers the total cell count and
Figure 7 Linearity and range on MNCs and MSCs. The assay was performed on MNCs (A) and MSCs (B), using Fast Read 102 W, as previously
reported. The Operators tested different dilutions of cell suspension (undiluted, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128). The test was performed without
considering cell viability, as described above, to compare all the “linearity and range” data. The regression line was calculated by using the
average of values obtained from Op1 and Op2’s counts at each dilution. The best range of dilution, in order to obtain a slope line value very
similar to 1, is between 1:8 and 1:128. a1) MNCs dilution range: undiluted, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128; a2) MNCs dilution range: 1:4, 1:8, 1:16,
1:32, 1:64, 1:128; a3) MNCs dilution range: 1:8, 1:16, 1:32, 1:64, 1:128; b1) MSCs dilution range: undiluted, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128; b2)
MSCs dilution range: 1:4, 1:8, 1:16, 1:32, 1:64, 1:128; b3) MSCs dilution range: 1:8, 1:16, 1:32, 1:64, 1:128. Op1 = operator 1, Op2 = operator 2.
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best range of dilution to use.
There were three different steps through which it was
possible to re-evaluate intra and inter operator precision
and the range of dilutions in which linearity is main-
tained: 1) Intra operator precision: Op1 and Op2 per-
formed three cell counts and calculated the intra
operator CV% at each dilution for both wPB and wBM.
The value of intra operator CV% was always <10%; 2)
Inter operator precision: Op1 and Op 2 calculated the in-
ter operator CV% at each dilution for both wPB and
wBM. The value of inter operator CV% was always
<10%; 3) Regression Line: calculated by using the average
of values obtained from Op 1 and 2’s counts at eachdilution. The best dilution range in order to obtain a
slope line value very similar to 1, is between 1:8 and
1:128 [R2 (wPB) = 0.9; R2 (wBM) = 0.9]. All the data are
summarized in Figure 6.
Linearity and range on MNCs and on MSCs
According to ICH Q2 [9], as described above, we tested
serial dilutions, in the following range: undiluted, 1:2,
1:4, 1:8, 1:16, 1:32, 1:64, 1:128. Op1 and Op2 performed
the cell count three times for each dilution. The test was
performed without considering cell viability, as described
above, to compare all the “linearity and range” data.
There were three different steps through which it was
possible to re-evaluate inter and intra operator precision
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tained: 1) intra operator precision: Op1 and Op2 per-
formed three cell counts and calculated the intra
operator CV% at each dilution for both MNCs and
MSCs. The intra operator CV% value was always <10%;
2) inter operator precision: Op1 and Op 2 calculated the
inter operator CV% at each dilution for both MNCs and
MSCs. The value of inter operator CV% was always
<10%; 3) Regression Line: calculated using the average of
values obtained from the Op1 and Op2 cell counts at
each dilution. The best range of dilution, in order to ob-
tain a slope line value very similar to 1, is between 1:8
and 1:128 [R2 (MNCs) = 0.9; R2 (MSCs) = 0.9. All the
data are summarized in Figure 7.
Conclusions
Cellular therapy is an emerging field in medicine. The em-
ployment of stem cell types in clinical studies, requires for-
mal approvals by respective regulatory bodies. Such
approvals require the manufacturing, processing and test-
ing of cellular products [17-19] according to the current
GMP guide lines concerning medical products and investi-
gational medicinal products for human use [1-8]. During
CTP manufacturing, every step should be taken to demon-
strate their suitability for routine processing and should be
validated in order to produce cells of the required quality.
All biological products must meet the prescribed require-
ments of safety, purity and potency and no lot of any
licensed product may be released by the manufacturer
prior to the completion of tests for the conformity with
standards applicable to such products including potency
[20]. The cell count procedure is a critical point in CTP
production, in both the manufacturing phases and in lot
release. Indeed, in the former, the cell count influences the
cell culture methodology (plating, feeding, expansion, etc).
Moreover, in the batch release, the cell count is a key point
to verify the compliance of each batch with CTP clinical
protocols according to GCP [21-25]. On these bases, our
primary aim was to validate a disposable cell count method
in a GMP condition, to be included in the Validation
Master Plan (VMP) to be submitted to regulatory bodies,
in order to obtain accreditation of our Cell Factory to pro-
duce CTPs. The cell count is a potency test, according to
EP, which define the cell, dose during ex-vivo expansion
and batch release. In a GMP setting, the cell counting
using disposable devices is a very important starting point
because: 1) overcomes the problem of chamber washing
after use allowing cell count in a clean environment, such
as in a Cell Factory; 2) allows a single use of the count
chamber which can then be trashed; 3) avoids the disposal
of toxic substance such as vital dye (e.g. Trypan Blue) or
lysing solution (e.g. Tuerk solution). On these bases,
among other disposable cell count chambers, we tested
Fast Read 102 W device as in our lab we have experienceon cell counting by it. Firstly we tested whether Fast Read
102W slides might substitute the Bürker chamber in terms
of accuracy. Once this hypothesis was proved, we tested re-
peatability, linearity and range only by using Fast Read 102
W. Two cell subpopulations were chosen for the validation
procedure: MNCs, as a subset of lymphocytes, and MSCs,
both CTPs that we will produce for immunotherapy and
regenerative medicine.
For each test (accuracy, precision, repeatability, linear-
ity and range), previously defined, the Operators,
according to ICH Q2, performed three cell counts,
under the same operating conditions.
Three repetitions for each count proved sufficient for
a statistical analysis and the CV and SD we obtained cor-
roborate, in our opinion, our experimental approach.
As cell counting method with Fast Read 102W has
proved to be accurate we decided to use the disposable
Fast Read 102W chamber, instead of the Bürker chamber,
for all subsequent tests.
Our data demonstrated that the Fast Read 102W count
method is accurate, precise and ensures the linearity of
the results obtained in a range of cell dilutions. Accord-
ing to acceptance criteria the total cell count CV% (inter
and intra operator) was 10% and the viable cell count
CV% (inter and intra operator) was <5%. According to
ICHQ2, the cell count is a potency test, so the Detection
Limit and Quantitation Limit are not required. However
in the contest of linearity and range test we verified that,
for all cell subset used, the optimal counting cell con-
centration range is between 1:8 and 1:128 dilutions.
Moreover matching all our accuracy, precision and lin-
earity range data, we can conclude that the minimal and
the maximal cells which can be counted are about from
30,000 to 600,000 cells respectively.
Despite being a niche article, our paper might be very
important for the scientific community in the cell ther-
apy field because our data demonstrated that cell count,
by Fast Read 102W, should satisfy Pharmacopoeia rules,
and might be used, in clean rooms, to dose CTPs.
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